3621-71-4

Upstream product

• 64-17-5 ethanol 
• 116418-82-7 1,3-dicyclohexyl-5-diazopyrimidine-2,4,6(1H,3H,5H)-trione 
• 79-37-8 oxalyl dichloride 
• 2387-23-7 1,3-Dicyclohexylurea 
• 5781-53-3 monomethyl oxalyl chloride 
• 538-75-0 dicyclohexyl-carbodiimide 
• 81539-54-0 isonitroso Meldrum’s acid 
• 205534-75-4 1-Cyanocarbonyl-1,3-dicyclohexyl-urea 
• 108-91-8 cyclohexylamine 
• 4755-77-5 Ethyl oxalyl chloride 

Downstream Products

• 131271-14-2 1,3-Dicyclohexyl-5-hydroxy-5-(trifluormethyl)-imidazolidin-2,4-dion 
• 131271-16-4 1,3-Dicyclohexyl-5-hydroxy-5-(pentafluorethyl)-imidazolidin-2,4-dion 

Relevant academic research and scientific papers

Synthesis of 5-hydroxy hydantoins via a tandem process

An efficient entry to 5-hydroxyhydantoin derivatives is reported. The reaction of α-ketoacids with commercially available carbodiimides under mild conditions, and in the presence of visible light, induces the rearrangement of an O-acyl urea, and eventuall

Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the progressive loss of motor neurons, leading to muscle weakness, paralysis, and death, most often from respiratory failure. The only FDA-approved drug for the treatment of ALS, riluzole, only extends the median survival in patients by 2-3 months. There is an urgent need for novel therapeutic strategies for this devastating disease. Using a high-throughput screening assay targeting an ALS cultured cell model (PC12-G93A-YFP cell line), we previously identified three chemotypes that were neuroprotective. We present a further detailed analysis of one promising scaffold from that group, pyrimidine-2,4,6-triones (PYTs), characterizing a number of PYT analogues using SAR and ADME. The PYT compounds show good potency, superior ADME data, low toxicity, brain penetration, and excellent oral bioavailability. Compounds from this series show 100% efficacy in the protection assay with a good correlation in activity between the protection and protein aggregation assays. The modifications of the PYT scaffold presented here suggest that this chemical structure may be a novel drug candidate scaffold for use in clinical trials in ALS.

Reaction of 5-hydroxyimino-1,3-dioxine-4,6-dione (isonitroso meldrum's acid) with carbodiimides to give parabanic acids

Reaction of 5-hydroxyimino-1,3-dioxine-4,6-dione (isonitroso Meldrum's Acid) with carbodiimides gave cyanoformamide derivatives in quantitative yields, which cyclized to iminoparabanic acids and parabanic acids under basic and acidic conditions, respectively.

Pharmaceutical composition containing an imidazolidinetrione derivative or pharmaceutically acceptable salt thereof

Pharmaceutical compositions containing imidazolidinetrione derivatives or pharmaceutically acceptable salts thereof having hypoglycemic and hypolipidemic effects. The compositions comprise as an active ingredient at least one imidazolidinetrione derivative of the formula: STR1 wherein each of R1 and R2, which may be the same or different, is hydrogen, an alkyl group, a cycloalkyl group or STR2 and each of R3 and R4, which may be the same or different, is hydrogen, halogen, a nitro group, a lower alkyl group or a lower alkoxy group.

Reaction of Oxalyl Chloride and Alkyloxalyl Chlorides with Isocyanates and Isothiocyanates

Alkyl and aryl isothiocyanates react with oxalyl chloride (1) on both double bonds of the heterocumulene to yield 3-alkyl- or 3-aryl-2,2-dichlorothiazolidine-4,5-diones 2.The two chlorines in these novel orthocarbonic acid derivatives are readily exchanged by alkoxy groups to yield 2,2-dialkoxythiazolidine-4,5-diones 3; hydrolysis of 2a (R=CH3) gave 3-methylthiazolidine-2,4,5-trione. 3-Substituted 5,5-dichlorooxazolidine-2,4-diones 8 and 5-chloro-5-alkoxyoxazolidine-2,4-diones 13 are obtained on reacting alkyl, aryl, and benzyl isocyanates with 1 and alkyloxalyl chloride, respectively.Structure assignment to these novel cycloadducts is based on IR, 1H NMR, and 13C NMR spectroscopic as well as X-ray crystallographic analysis.Formation of 8 and 13 is a stepwise process involving labile acyclic intermediates 7 and 12.The cyclizations to 8 and 13 take place only on the C=N bond of the isocyanate group.